Life Sciences Still Falls Short on Pay Equity

Why It Matters

Pay inequity threatens employee engagement, heightens litigation risk, and undermines the U.S. life‑sciences sector’s ability to attract and retain top talent in a globally competitive market.

Key Takeaways

• Women earn 88% of male total compensation in 2025.
• White/non‑Hispanic professionals average $203k, highest among groups.
• Pay gaps stem from experience gaps and limited advancement.
• Industry acknowledges disparity but action remains insufficient.
• Equity improvements needed to retain U.S. biotech talent.

Pulse Analysis

The latest BioSpace salary survey underscores that the life‑sciences sector, despite its reputation for innovation, still grapples with entrenched compensation gaps. Women’s earnings sit at roughly 88% of their male peers, and racial disparities persist, with white/non‑Hispanic professionals pulling in the highest average salaries. These figures echo findings from recent BIO and MassBio DEI reports, which warn that unchecked pay inequities erode trust in leadership and expose firms to regulatory scrutiny as more jurisdictions mandate compensation transparency.

Beyond compliance, the equity gap poses a strategic talent risk. As U.S. biotech hubs face mounting competition from global centers, skilled professionals—especially women and minorities—are increasingly weighing offers abroad where pay parity may be clearer. The migration threat amplifies the cost of inaction, potentially draining the industry of the diverse expertise needed for breakthrough therapies. Companies that fail to address these gaps risk higher turnover, reduced employee engagement, and a weakened employer brand in a tight labor market.

To turn awareness into measurable progress, firms should adopt granular pay audits that break down compensation by role, experience level, and demographic group. Coupled with targeted workforce‑development initiatives—such as mentorship, sponsorship, and sponsorship programs for underrepresented talent—these steps can accelerate experience accumulation for women and minorities. Transparent compensation frameworks, regular reporting, and executive accountability are essential levers that not only mitigate legal exposure but also signal a genuine commitment to inclusive excellence, positioning the U.S. life‑sciences industry to retain its competitive edge.